Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
2.
Cytotherapy ; 23(1): 37-45, 2021 01.
Article in English | MEDLINE | ID: mdl-33092988

ABSTRACT

BACKGROUND AIMS: Certain therapies (e.g., daclizumab) that promote expansion of natural killer (NK) cells are associated with clinical amelioration of disease in the context of multiple sclerosis and associated mouse models. The clinical benefits are putatively attributable to an enhanced capacity of NK cells to kill activated pathogenic T cells. Whether a parallel approach will also be effective in systemic lupus erythematosus (lupus), a multi-organ autoimmune disease driven by aberrant responses of self-reactive T and B cells, is unclear. METHODS: In the present study, the authors assess the therapeutic impact of IL-2- and IL-15-based strategies for expanding NK cells on measures of lupus-like disease in a mouse model. RESULTS: Unexpectedly, cytokine-mediated expansion of cytotoxic lymphocytes aggravated immunological measures of lupus-like disease. Depletion studies revealed that the negative effects of these cytokine-based regimens can largely be attributed to expansion of CD8 T cells rather than NK cells. CONCLUSIONS: These results provoke caution in the use of cytokine-based therapeutics to treat co-morbid cancers in patients with lupus and highlight the need for new methods to selectively expand NK cells to further assess their clinical value in autoimmune disease.


Subject(s)
CD8-Positive T-Lymphocytes/drug effects , Immunomodulation , Interleukin-15/pharmacology , Interleukin-2/pharmacology , Killer Cells, Natural/drug effects , Lupus Erythematosus, Systemic/therapy , Animals , CD8-Positive T-Lymphocytes/immunology , Humans , Killer Cells, Natural/immunology , Lymphocyte Activation , Male , Mice
3.
J Obstet Gynaecol Res ; 38(1): 77-83, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22136755

ABSTRACT

AIM: The multifactorial etiology of bacterial vaginosis (BV) impedes development of effective treatment and prevention strategies. Herein, we evaluated the effects of herpes simplex virus type 2 (HSV-2), a suspected BV risk factor, on vaginal flora composition. MATERIALS AND METHODS: Correlations between HSV-2 infection and BV were prospectively explored among 12 HSV-2-seropositive women with asymptomatic BV who were asked to collect daily vaginal swab specimens for Gram stain analysis of vaginal flora and determination of HSV-2 shedding frequencies during the 1month before and after metronidazole therapy. RESULTS: Unlike prior longitudinal studies that reported rapid fluctuations in vaginal flora composition and frequent episodes of spontaneously resolving BV, we found that 99.4% (310/312) of vaginal smears collected before initiation of metronidazole were consistent with a diagnosis of BV. Effectiveness of metronidazole therapy was also much lower than previously reported in studies not restricting enrollment to HSV-2-seropositive women; we observed a BV recurrence rate of 89% in the first month after completion of therapy while the median time to this recurrence occurred only 14days after treatment. CONCLUSIONS: Our study demonstrates BV recalcitrance among HSV-2-infected women and provides additional evidence for a linkage between this chronic viral infection and abnormal vaginal flora. Additional work will be needed to define mechanisms responsible for this correlation and to determine if vaginal flora health of HSV-2-infected women is improved by medications that suppress HSV-2 shedding.


Subject(s)
Herpes Genitalis/virology , Herpesvirus 2, Human/immunology , Vagina/virology , Vaginosis, Bacterial/virology , Adolescent , Adult , Anti-Infective Agents/therapeutic use , Female , Herpes Genitalis/microbiology , Humans , Metronidazole/therapeutic use , Risk Factors , Vagina/microbiology , Vaginosis, Bacterial/drug therapy , Vaginosis, Bacterial/microbiology , Virus Shedding
4.
Am J Obstet Gynecol ; 205(4): 324.e1-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21777898

ABSTRACT

OBJECTIVE: The objective of the study was to characterize endometrial inflammation associated with common genital tract pathogens. STUDY DESIGN: The design of the study was the immunohistochemical characterization of the endometrial leukocyte subpopulations from 37 controls and 45 women infected with Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. RESULTS: Compared with uninfected women, endocervical infection with C trachomatis, N gonorrhoeae, or T vaginalis was associated with significant increases in endometrial T cells, B cells, plasma cells, and polymorphonuclear leukocytes. Even more substantial increases in T cell, B cell, and plasma cell numbers were detected among women infected endocervically and endometrially with C trachomatis. CONCLUSION: Because lower genital tract C trachomatis, N gonorrhoeae, or T vaginalis infections were associated with comparable increases in the same endometrial leukocyte subpopulations, our results suggest the underappreciated involvement of T vaginalis in upper genital tract inflammatory processes. The more robust inflammatory infiltrate associated with C trachomatis endometrial ascension may offer insight into host inflammatory responses associated with pelvic inflammatory disease development.


Subject(s)
Chlamydia Infections/immunology , Chlamydia trachomatis , Endometrium/immunology , Gonorrhea/immunology , Leukocytes , Reproductive Tract Infections/immunology , Endometrium/cytology , Female , Humans , Immunohistochemistry , Trichomonas Vaginitis
5.
Cell Rep Med ; 1(1)2020 04 21.
Article in English | MEDLINE | ID: mdl-32864635

ABSTRACT

Follicular helper T cells (TFH) are critical for vaccine and infection elicitation of long-lived humoral immunity, but exaggerated TFH responses can promote autoimmunity and other pathologies. It is unfortunate that no clinical interventions exist for the selective depletion of follicular T cells to alleviate these diseases. We engineered a chimeric antigen receptor (CAR) facilitating the specific targeting of cells with high expression levels of human programmed cell death protein 1 (PD-1), a cardinal feature of follicular T cells. CAR-expressing human natural killer (NK) cells robustly and discriminately eliminated PD-1high follicular human T cells in vitro and in a humanized mouse model of lupus-like disease while sparing B cells and other PD-1low T cell subsets, including regulatory T cells. These results establish a strategy for specific targeting of PD-1high T cells that can be advanced as a clinical tool for the selective depletion of pathogenic follicular T cells or other PD-1high target cells in certain disease states.


Subject(s)
Killer Cells, Natural/transplantation , Receptors, Chimeric Antigen/metabolism , T-Lymphocytes/immunology , Adult , Animals , Autoimmune Diseases/immunology , Autoimmune Diseases/therapy , Autoimmunity/genetics , Autoimmunity/immunology , Cells, Cultured , Child , Child, Preschool , Drosophila melanogaster , Female , Humans , Immunotherapy, Adoptive/methods , Killer Cells, Natural/metabolism , Killer Cells, Natural/physiology , Male , Mice , Mice, Inbred NOD , Mice, SCID , Mice, Transgenic , Receptors, Chimeric Antigen/genetics , T-Lymphocytes/metabolism
7.
Curr Opin Virol ; 16: 15-23, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26590692

ABSTRACT

Natural killer (NK) cells are important in immune defense against virus infections. This is predominantly considered a function of rapid, innate NK-cell killing of virus-infected cells. However, NK cells also prime other immune cells through the release of interferon gamma (IFN-γ) and other cytokines. Additionally, NK cells share features with long-lived adaptive immune cells and can impact disease pathogenesis through the inhibition of adaptive immune responses by virus-specific T and B cells. The relative contributions of these diverse and conflicting functions of NK cells in humans are poorly defined and likely context-dependent, thereby complicating the development of therapeutic interventions. Here we focus on the contributions of NK cells to disease in diverse virus infections germane to human health.


Subject(s)
Host-Pathogen Interactions/immunology , Killer Cells, Natural/immunology , Virus Diseases/immunology , Virus Diseases/virology , Viruses/immunology , Adaptive Immunity , Animals , Humans , Immunity, Innate , Killer Cells, Natural/metabolism , Lymphocyte Subsets/immunology , Lymphocyte Subsets/metabolism , Virus Diseases/metabolism , Viruses/classification
8.
PLoS One ; 8(3): e58565, 2013.
Article in English | MEDLINE | ID: mdl-23555586

ABSTRACT

While Chlamydia trachomatis infections are frequently asymptomatic, mechanisms that regulate host response to this intracellular Gram-negative bacterium remain undefined. This investigation thus used peripheral blood mononuclear cells and endometrial tissue from women with or without Chlamydia genital tract infection to better define this response. Initial genome-wide microarray analysis revealed highly elevated expression of matrix metalloproteinase 10 and other molecules characteristic of Type 2 immunity (e.g., fibrosis and wound repair) in Chlamydia-infected tissue. This result was corroborated in flow cytometry and immunohistochemistry studies that showed extant upper genital tract Chlamydia infection was associated with increased co-expression of CD200 receptor and CD206 (markers of alternative macrophage activation) by endometrial macrophages as well as increased expression of GATA-3 (the transcription factor regulating TH2 differentiation) by endometrial CD4(+) T cells. Also among women with genital tract Chlamydia infection, peripheral CD3(+) CD4(+) and CD3(+) CD4(-) cells that proliferated in response to ex vivo stimulation with inactivated chlamydial antigen secreted significantly more interleukin (IL)-4 than tumor necrosis factor, interferon-γ, or IL-17; findings that repeated in T cells isolated from these same women 1 and 4 months after infection had been eradicated. Our results thus newly reveal that genital infection by an obligate intracellular bacterium induces polarization towards Type 2 immunity, including Chlamydia-specific TH2 development. Based on these findings, we now speculate that Type 2 immunity was selected by evolution as the host response to C. trachomatis in the human female genital tract to control infection and minimize immunopathological damage to vital reproductive structures.


Subject(s)
Chlamydia Infections/immunology , Chlamydia trachomatis/immunology , Cytokines/immunology , Gene Expression Regulation/immunology , Th2 Cells/immunology , Adolescent , Adult , Antigens, CD/biosynthesis , Antigens, CD/immunology , Chlamydia Infections/blood , Chlamydia Infections/pathology , Cytokines/blood , Female , Humans , Macrophage Activation/immunology , Th2 Cells/metabolism , Th2 Cells/pathology
9.
Am J Reprod Immunol ; 68(6): 499-506, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22934581

ABSTRACT

PROBLEM: Development of safe and effective Chlamydia trachomatis vaccines requires better understanding of the host immune responses elicited by natural infection. METHOD OF STUDY: Peripheral blood mononuclear cells isolated from women with or without history of genital tract chlamydial infection were stimulated with inactivated C. trachomatis elementary bodies (EB) in ELISPOT assays that enumerated frequencies of cells producing interferon (IFN)-γ or interleukin (IL)-17. RESULTS: IFN-γ-positive cells were highest among women sampled 30-60 days after diagnosis of C. trachomatis infection and treatment initiation, while the numbers of IFN-γ-positive cells were equally low among uninfected women and women sampled <30 or >60 days after diagnosis of infection. Conversely, IL-17-positive cell numbers were uniformly low among all participants. CONCLUSION: Dramatically reduced numbers of Chlamydia-specific Th1 memory cells in the peripheral circulation of study participants sampled more than 2 months after diagnosis, and initiation of treatment provides new insight into the results from C. trachomatis vaccine trials, in which immunization with EB provided only short-lived protection. Our results also suggest that an effective vaccine against this weakly antigenic intracellular pathogen will need to generate immunological memory more durable than that elicited by natural infection.


Subject(s)
Chlamydia Infections/immunology , Chlamydia trachomatis/immunology , Reproductive Tract Infections/immunology , Th1 Cells/immunology , Adolescent , Adult , Female , Humans , Immunologic Memory , Interferon-gamma/biosynthesis , Interleukin-17/biosynthesis , Leukocytes, Mononuclear/immunology , Lymphocyte Count , Phytohemagglutinins/immunology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL